Nestle SA agreed to buy Pfizer Inc’s Nutrition unit for US$11.9 billion, expanding its business selling infant formula in emerging markets.
The purchase will boost earnings per share in the first full year, the Vevey, Switzerland-based company said in a statement yesterday.
About 85 percent of the unit’s sales come from emerging markets, Nestle added.
The purchase will help Nestle, already the top seller of infant-nutrition products, regain traction in the Chinese baby food market. Nestle has been losing market share there since 2005, when it withdrew two varieties of Neslac milk powder because authorities found they contained excessive iodine. The Asia-Pacific region accounted for 43 percent of the US$42.2 billion market for baby food products last year, according to data from Euromonitor International.
“It looks pretty pricey,” said Jon Cox, an analyst at Kepler Capital Markets in Zurich.
He estimates the price is about 22 times the unit’s earnings before interest, tax, depreciation and amortization (EBITDA).
However, “from a long-term perspective, it makes strategic sense as it will really strengthen Nestle’s position in Asia,” Cox added.
The sale will be Pfizer’s largest divestiture since the US$16.6 billion sale of consumer health brands — including Sudafed cold medicine and Bengay pain cream to Johnson & Johnson in 2006.
It is the first of two major exits that Pfizer chief executive Ian Read outlined to shrink the New York-based company and concentrate on producing new drugs. Pfizer was close to choosing between bids from Nestle and Danone SA, people with knowledge of the deal said last week.
Pfizer’s business includes infant formulas such as SMA and Promil. The unit, which also makes Enercal supplements for adults, offers products in more than 60 countries, according to its Web site, and accounted for 3.2 percent of the company’s revenue last year. Pfizer gained the formula division through its US$68 billion purchase of Wyeth in 2009.
Pfizer had the fifth-largest global market share of the infant formula business in 2010, trailing Nestle, Mead-Johnson Nutrition Co, Danone and Abbott Laboratories, according to Euromonitor.
Its market positions are strongest in the Middle East and Africa where it ranks third and Asia-Pacific region where it ranks fourth, Euromonitor analyst Lee Linthicum said.
In addition to the infant nutrition business, Read is spinning off Pfizer’s animal-health unit, which had US$4.18 billion in revenue last year.
The drugmaker is planning an initial public offering for the unit, a person with knowledge of the matter said.
The Eurovision Song Contest has seen a surge in punter interest at the bookmakers, becoming a major betting event, experts said ahead of last night’s giant glamfest in Basel. “Eurovision has quietly become one of the biggest betting events of the year,” said Tomi Huttunen, senior manager of the Online Computer Finland (OCS) betting and casino platform. Betting sites have long been used to gauge which way voters might be leaning ahead of the world’s biggest televised live music event. However, bookmakers highlight a huge increase in engagement in recent years — and this year in particular. “We’ve already passed 2023’s total activity and
BIG BUCKS: Chairman Wei is expected to receive NT$34.12 million on a proposed NT$5 cash dividend plan, while the National Development Fund would get NT$8.27 billion Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday announced that its board of directors approved US$15.25 billion in capital appropriations for long-term expansion to meet growing demand. The funds are to be used for installing advanced technology and packaging capacity, expanding mature and specialty technology, and constructing fabs with facility systems, TSMC said in a statement. The board also approved a proposal to distribute a NT$5 cash dividend per share, based on first-quarter earnings per share of NT$13.94, it said. That surpasses the NT$4.50 dividend for the fourth quarter of last year. TSMC has said that while it is eager
Pegatron Corp (和碩), an iPhone assembler for Apple Inc, is to spend NT$5.64 billion (US$186.82 million) to acquire HTC Corp’s (宏達電) factories in Taoyuan and invest NT$578.57 million in its India subsidiary to expand manufacturing capacity, after its board approved the plans on Wednesday. The Taoyuan factories would expand production of consumer electronics, and communication and computing devices, while the India investment would boost production of communications devices and possibly automotive electronics later, a Pegatron official told the Taipei Times by telephone yesterday. Pegatron expects to complete the Taoyuan factory transaction in the third quarter, said the official, who declined to be
CUSTOMERS’ BURDEN: TSMC already has operations in the US and is a foundry, so any tariff increase would mostly affect US customers, not the company, the minister said Taiwanese manufacturers are “not afraid” of US tariffs, but are concerned about being affected more heavily than regional economic competitors Japan and South Korea, Minister of Economic Affairs J.W. Kuo (郭智輝) said. “Taiwan has many advantages that other countries do not have, the most notable of which is its semiconductor ecosystem,” Kuo said. The US “must rely on Taiwan” to boost its microchip manufacturing capacities, Kuo said in an interview ahead of his one-year anniversary in office tomorrow. Taiwan has submitted a position paper under Section 232 of the US Trade Expansion Act to explain the “complementary relationship” between Taiwan and the US
RSS